Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18130411 | 0.86 | ENPP2 (0.72) | ENPP2 | |
| SCHEMBL18130423 | 0.84 | ENPP2 (0.56) | ENPP2 | |
| SCHEMBL18130555 | 0.84 | GAA (0.47) | ENPP2 | |
| SCHEMBL18130451 | 0.83 | ENPP2 (1.00) | ENPP2 | |
| SCHEMBL18130481 | 0.81 | ENPP2 (1.00) | ENPP2 | |
| SCHEMBL18130582 | 0.81 | ENPP2 (1.00) | ENPP2 | |
| SCHEMBL30792114 | 0.81 | ENPP2 (1.00) | ENPP2 | |
| SCHEMBL18130659 | 0.81 | ENPP2 (1.00) | ENPP2 | |
| SCHEMBL18130520 | 0.81 | ENPP2 (1.00) | ENPP2 | |
| SCHEMBL1919919 | 0.81 | ENPP2 (0.47) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-107428754-B | Bicyclic quinazolinone derivatives | 豪夫迈·罗氏有限公司 | 2020-07-31 | — | — | CN | disclosed |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3280707-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2018-02-14 | — | — | EP | disclosed |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-02-01 | — | — | US | disclosed |
| WO-2016162390-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016162390-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317624-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | ENPP2 4284/4885 |
| US-20180029996-A1 | BICYCLIC QUINAZOLINONE DERIVATIVES | BRD4, BICRA, NDUFC2 | ENPP2 4284/4885 |
| US-10676446-B2 | Bicyclic quinazolinone derivatives | BRD4, BICRA, NDUFC2 | ENPP2 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.